摘要
角膜胶原交联技术是用于治疗角膜扩张性疾病的一项新方法。核黄素／紫外线角膜胶原交联技术可延缓或阻止角膜扩张疾病的进展，并其改善视力、散光和角膜地形图参数。但该技术仍存在应用局限，现已有各种改进的技术方案。激光光化学交联技术作为一项新的安全有效的交联技术正逐渐成为研究热点。本文综述以上两种胶原交联技术的原理、交联效能，临床应用及并发症和应用局限。
Corneal collagen crosslinking is a new treatment for the corneal ectatic disorders. Riboflavin/ultraviolet A （UVA） corneal collagen cross-linking has been approved to halt the progression of keratoconus and other corneal ectatic disorders, with improvements in visual, keratometric and topographic parameters. However, the technique raises some disadvantages. Various modifications have been investigated for a safety and better outcome. Nowadays, photochemical collagen crosslinking is turning to be a research hotspot as a new safe and effective technology. This paper reviews the principle, cross-linking efficiency, and the limitations of these two kinds of collagen crosslinking technologies.
出处
《中华眼外伤职业眼病杂志》
2015年第12期956-960,共5页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
基金
上海市科委自然基金（15ZR1412200）
关键词
核黄素/紫外线交联技术
角膜扩张性疾病
激光化学反应胶原交联技术
Riboflavin/ultraviolet A corneal collagen cross-linking
Corneal ectatic disorders
Photochemical collagen crosslinking
